Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristics

Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristics

Background The Mepolizumab in Relapsing or Refractory EGPA (MIRRA) trial (GSK ID: 115921/NCT02020889) demonstrated that mepolizumab increased remission time and reduced oral corticosteroid (OCS) use compared with placebo in patients with relapsing or refractory eosinophilic granulomatosis with polya...

Full description

Bibliographic Details
Main Authors: David R.W. Jayne, Benjamin Terrier, Bernhard Hellmich, Paneez Khoury, Lee Baylis, Jane H. Bentley, Jonathan Steinfeld, Steven W. Yancey, Namhee Kwon, Michael E. Wechsler, Praveen Akuthota
Format: Article
Language:English
Published: European Respiratory Society 2024-01-01
Series:ERJ Open Research
Online Access:http://openres.ersjournals.com/content/10/1/00509-2023.full

Internet

http://openres.ersjournals.com/content/10/1/00509-2023.full

Similar Items